Related Experiment Videos
Monocyte disorders associated with T cell defects in patients with solid tumors
E Anastasopoulos1, G J Reclos, C N Baxevanis
1Department of Immunology, Hellenic Anticancer Institute, Athens, Greece.
Anticancer Research
|March 1, 1992
Summary
In advanced cancer, T cell responses are impaired due to monocyte dysfunction, affecting Interleukin-2 (IL-2) production and receptor expression. Early-stage cancer patients show normal T cell function, unlike those with advanced disease.
Area of Science:
- Immunology
- Oncology
Background:
- Autologous mixed lymphocyte reaction (AMLR) involves T cell proliferation in response to monocytes.
- T cell function is crucial for immune response and can be altered in cancer patients.
Purpose of the Study:
- To investigate T cell and monocyte function in patients with different stages of cancer.
- To understand the mechanisms behind impaired T cell responses in advanced cancer.
Main Methods:
- Assessed AMLR in cancer patients (stages I-IV) and healthy donors.
- Measured Interleukin-2 (IL-2) production and Interleukin-2 receptor (IL-2R) expression on T cells.
- Evaluated monocyte function, including HLA-DR antigen expression and production of Interleukin-1 beta (IL-1 beta) and Tumor Necrosis Factor alpha (TNFa).
Main Results:
- AMLR was impaired in advanced cancer (stages III-IV) but normal in early stages (I-II).
- T cells from advanced cancer patients showed reduced IL-2 production and IL-2R expression.
- Monocytes from advanced cancer patients had diminished HLA-DR expression and lower IL-1 beta and TNFa production.
Conclusions:
- Impaired T cell responses in advanced cancer are linked to monocyte dysfunction.
- Monocyte abnormalities, including reduced HLA-DR and cytokine production, contribute to T cell dysfunction in cancer.
- Findings offer insights into the mechanisms of impaired T cell immunity in cancer patients.